HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Adam Zamecnik

Reporter

London, UK

Adam has previously worked at GlobalData Media as a Healthcare Reporter, writing longer and shorter articles for the public website Pharmaceutical Technology and the Pharma Intelligence Centre. During his time there, Adam focused on topics such as cell and gene therapy, vaccine research, and new approaches to the treatment of haematological conditions. He has also covered the development of new biosimilars, the production of complex generics, and legal battles between Big Pharma. Prior to this, Adam wrote as a freelance reporter for the likes of Vice World News. Adam holds an MA in International Journalism from City, University of London.

Latest From Adam Zamecnik

ANI Acquires Alimera Sciences To Bolster Ophthalmology Portfolio

ANI has acquired Alimera Sciences in a move to expand its rare disease business, highlighting its increasing drift from generics.

United States BioPharmaceutical

Apotex Secures Canadian License For Loqtorzi From Coherus

After announcing a pivot to innovative oncology treatments from biosimilars, Coherus has granted an exclusive license for its novel biologic cancer therapy Loqtorzi to Apotex in Canada.

Canada Biologics

Dr Reddy’s Acquiring Haleon NRTs Available Outside US In Deal Worth Up To $632M

The Indian player made another high-level deal that grants it rights to nicotine replacement therapies in over 30 countries, following on from its recent announcements with Nestlé.

OTC Drugs Deals

TVM Capital Boosts Boston Oncology Arabia’s Capacities With $35m Injection

Following on from the recently announced closing of a Saudi Arabia-focused fund, TVM Capital has doubled down on its local efforts with a further $35m investment into Boston Oncology Arabia’s efforts.

Saudi Arabia BioPharmaceutical

Dr Reddy’s Acquires Nicotinell In A £500m Deal

The Indian player made another high-level deal that grants it rights to nicotine replacement therapies in over 30 countries, following on from its recent announcements with Nestlé.

India Deals

Newbury Secures Approval For Victoza Generic In Denmark

Only days after the EU-wide decentralized approval of Adalvo’s Victoza generic, Newbury broke news with the greenlighting of its own Victoza rival in Denmark.

Denmark Generic Drugs
See All
UsernamePublicRestriction

Register